BioMedTech will work to establish approximately a dozen spinouts from European and American universities, with a particular focus on France.
France-based venture capital firm Truffle Capital yesterday closed a €250m ($278m) vehicle called BioMedTech that will focus on research commercialisation in Europe and the US.
Limited partners were not identified, though Truffle Capital revealed that approximately 60% of capital originated from France and the remainder was provided by international investors.
BioMedTech will collaborate with unspecified European and American universities – with a focus on France – to establish approximately 12 spinouts in the medical devices and robotics sectors.…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
